TG Therapeutics Reports Strong Q1, Significantly Raises 2026 Revenue Guidance, Secures $500M Non-Dilutive Capital, and Expands Buyback to $300M
TGTX sits 39% above its 52-week low of $25.28.
Summary
TG Therapeutics reported strong Q1 2026 results, significantly raised its full-year revenue guidance for BRIUMVI, secured $500 million in non-dilutive capital, and expanded its share repurchase program to $300 million.
Key Events · Earnings and Guidance · TGTX
-
Strong Q1 2026 Financial Performance
Reported Q1 2026 total global revenue of approximately $205 million, with BRIUMVI U.S. net product revenue of $194.8 million, representing approximately 63% quarterly growth over the same period last year. Net income for the quarter was $19.8 million, a significant increase from $5.1 million in Q1 2025.
-
Significantly Raised 2026 Revenue Guidance
Increased full-year 2026 target total global revenue to approximately $925 million and raised full-year 2026 BRIUMVI U.S. net product revenue target to $885-$900 million, up from prior guidance of $825-$850 million.
-
Secured $500 Million Non-Dilutive Capital
Obtained an additional $500 million in non-dilutive capital from Blue Owl Capital, enhancing financial flexibility without diluting existing shareholders.
-
Expanded Share Repurchase Program
Expanded the second share repurchase program from $100 million to $300 million. The company has repurchased $200 million of common stock since the program's inception in 2024, including $100 million during Q1 2026.
Analysis · TGTX · Life Sciences
TG Therapeutics delivered exceptionally strong first-quarter 2026 financial results, significantly exceeding prior year performance with product revenue up 68% and net income up 288%. The company substantially raised its full-year 2026 BRIUMVI U.S. net product revenue guidance from $825-$850 million to $885-$900 million, signaling robust demand and commercial execution for its key drug. Furthermore, the securing of $500 million in non-dilutive capital from Blue Owl Capital significantly strengthens the balance sheet without shareholder dilution. The expansion of the share repurchase program from $100 million to $300 million, with $100 million already executed in Q1, demonstrates strong management confidence and a commitment to returning value to shareholders. These combined factors present a highly positive outlook for the company's financial health and growth trajectory, reinforcing the investment thesis.
At the time of this filing, TGTX was trading at $35.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $25.28 to $40.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.